Used in clinical research for the treatment of advanced solid tumors, particularly in patients with NTRK gene fusions. It is an investigational TRK inhibitor designed to target and block the activity of TRKA, TRKB, and TRKC proteins, which are involved in tumor growth and survival. Shows activity against both primary and resistance mutations in NTRK genes, making it a potential option for patients who have progressed on prior TRK inhibitors. Currently being evaluated in phase 1 and 2 trials to assess safety, dosing, and efficacy in various cancer types.